In Split, Ikaria Looks For Products, While New R&D Play Preps For IPO
In a partial buy-out by new private equity investor Madison Dearborn Partners, Ikaria is refocused on building out its critical care product portfolio, while a new R&D spin-out may take a route to the public markets. Existing investors have already done nicely through a series of dividends.
You may also be interested in...
Ikaria Acquisition Diversifies And Strengthens Mallinckrodt’s Hospital Care Portfolio
But, with its $2.3 billion purchase price, Mallinckrodt is betting it can withstand a patent challenge to INOmax, an inhaled nitric oxide drug/device combo product, from an industrial gas company.
With Ikaria and Aptalis, Private Equity Investors Get Creative To Cash Out
Ikaria shareholders sold the commercial side of that critical care business, but retained a stake in the off-loaded assets. While gastrointestinal and cystic fibrosis company Aptalis turns to an IPO instead of an acquisition.
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.